Provided by Tiger Fintech (Singapore) Pte. Ltd.

Intellia Therapeutics

7.25
-0.0050-0.07%
Volume:1.98M
Turnover:14.51M
Market Cap:749.98M
PE:-1.38
High:7.50
Open:7.39
Low:7.21
Close:7.25
Loading ...

BRIEF-Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy Designation Granted To Nexiguran Ziclumeran

Reuters
·
25 Nov 2024

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted to Nexiguran Ziclumeran (Nex-Z) for the Treatment of Hereditary Transthyretin (Attr) Amyloidosis With Polyneuropathy

THOMSON REUTERS
·
25 Nov 2024

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

GlobeNewswire
·
25 Nov 2024

Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock?

Motley Fool
·
22 Nov 2024

Cathie Wood’s ARK Investment buys 223.5K shares of Intellia Therapeutics today

TIPRANKS
·
20 Nov 2024

Intellia Therapeutics Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
20 Nov 2024

Intellia Therapeutics Announces Promising CRISPR Therapy Results

TipRanks
·
19 Nov 2024

Intellia Therapeutics: Promising Early Results but Awaiting Late-Stage Validation for Stronger Investment Stance

TIPRANKS
·
19 Nov 2024

Intellia Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
18 Nov 2024

Intellia Therapeutics Shares Rise 6% After Co Reports Promising Early-Stage Data for Gene Editing Therapy

THOMSON REUTERS
·
18 Nov 2024

BUZZ-Intellia surges on promising early-stage data for gene editing therapy

Reuters
·
18 Nov 2024

Intellia Therapeutics Inc : Wells Fargo Cuts Target Price to $70 From $80

THOMSON REUTERS
·
18 Nov 2024

Evercore ISI Remains a Buy on Intellia Therapeutics (NTLA)

TIPRANKS
·
18 Nov 2024

TD Cowen Keeps Their Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
18 Nov 2024

Truist Financial Releases a Buy Rating on Intellia Therapeutics (NTLA)

TIPRANKS
·
18 Nov 2024

Intellia Therapeutics Shares up 13.9% Premarket on Promising Early-Stage Data of Experimental Gene Therapy for Rare Disease

THOMSON REUTERS
·
18 Nov 2024

Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo

TIPRANKS
·
18 Nov 2024

Intellia Therapeutics price target raised to $91 from $88 at Chardan

TIPRANKS
·
18 Nov 2024

Intellia Therapeutics: Promising Early Trial Results for nex-z, But Hold Rating Due to Uncertainty in Competitive Gene Editing Landscape

TIPRANKS
·
18 Nov 2024

Stock Track | Intellia Therapeutics Soars 16% Pre-Market on Promising Drug Data, Bullish Analyst Outlook

Stock Track
·
18 Nov 2024